Patents by Inventor Benjamin HORNING

Benjamin HORNING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K
    Publication number: 20250026721
    Abstract: Compounds and methods for modulating RAS-PI3K.
    Type: Application
    Filed: February 27, 2024
    Publication date: January 23, 2025
    Inventors: Junko TAMIYA, Benjamin HORNING, Karl BEDKE, Cynthia BERRY, Chung-Mao PAN, Hideki Miyatake ONDOZABAL, Brian COOK
  • COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE
    Publication number: 20240270705
    Abstract: Disclosed herein are compounds selective for JAK1, pharmaceutical compositions comprising said compounds, and methods of using said compounds.
    Type: Application
    Filed: May 25, 2022
    Publication date: August 15, 2024
    Inventors: Benjamin HORNING, Nilotpal ROY, Matthew PATRICELLI, Betty LAM, Shota KIKUCHI, Brian Nicholas COOK
  • IN VIVO ENGINEERED CEREBLON PROTEIN
    Publication number: 20220298213
    Abstract: Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO: 1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 22, 2022
    Inventors: David WEINSTEIN, Benjamin F. CRAVATT, Matthew PATRICELLI, Dean STAMOS, Gabe SIMON, Benjamin HORNING, Ekaterina VINOGRADOVA, Brian NORDIN, Kristen BALTGALVIS, Todd KINSELLA
  • CEREBLON MODULATORS AND USES THEREOF
    Publication number: 20220062248
    Abstract: Disclosed herein are compositions and methods for modulating cereblon neosubstrates. A small molecule modulator of Formula (I*), or a pharmaceutically acceptable salt or solvate thereof can be used to modulate cereblon neosubstrates.
    Type: Application
    Filed: November 17, 2020
    Publication date: March 3, 2022
    Inventors: Benjamin F. CRAVATT, Matthew PATRICELLI, Dean STAMOS, Gabe SIMON, Benjamin HORNING, David WEINSTEIN, Ekaterina VINOGRADOVA
  • IN VIVO ENGINEERED CEREBLON PROTEIN
    Publication number: 20210002337
    Abstract: Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3.
    Type: Application
    Filed: June 16, 2020
    Publication date: January 7, 2021
    Inventors: David WEINSTEIN, Benjamin F. CRAVATT, Matthew PATRICELLI, Dean STAMOS, Gabe SIMON, Benjamin HORNING, Ekaterina VINOGRADOVA, Brian NORDIN, Kristen BALTGALVIS, Todd KINSELLA
  • COMPOUNDS AND METHODS OF MODULATING PROTEIN DEGRADATION
    Publication number: 20200239530
    Abstract: Disclosed herein are protein-probe adducts and synthetic ligands that inhibit protein-probe adduct formation, in which the protein is part of the E3 ligase complex and the protein is modified to alter the substrate recognition of the E3 ligase complex. In some instances, also provided herein are protein-probe adducts and synthetic ligands that inhibit protein-probe adduct formation, in which the protein is modified or tagged for degradation. In some instances, additionally provided herein are cysteine-containing protein binding domains that interact with a probe and/or a ligand described herein.
    Type: Application
    Filed: September 27, 2018
    Publication date: July 30, 2020
    Inventors: Matthew PATRICELLI, Dean STAMOS, Gabe SIMON, Benjamin HORNING
  • IN VIVO ENGINEERED CEREBLON PROTEIN
    Publication number: 20200216507
    Abstract: Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3.
    Type: Application
    Filed: August 8, 2019
    Publication date: July 9, 2020
    Inventors: David WEINSTEIN, Benjamin F. CRAVATT, Matthew PATRICELLI, Dean STAMOS, Gabe SIMON, Benjamin HORNING
  • CEREBLON MODULATORS AND USES THEREOF
    Publication number: 20200206201
    Abstract: Disclosed herein are compositions and methods for modulating cereblon neosubstrates. A small molecule modulator of Formula (I*), or a pharmaceutically acceptable salt or solvate thereof can be used to modulate cereblon neosubstrates.
    Type: Application
    Filed: July 3, 2019
    Publication date: July 2, 2020
    Inventors: Benjamin F. CRAVATT, Matthew PATRICELLI, Dean STAMOS, Gabe SIMON, Benjamin HORNING, David WEINSTEIN